Tender Details

Country: Japan
Summary: Infliximab (Genetical Recombination) for Intravenous Infusion 100 (1001Vial/Case) 807 Cases,And 41 other Contracts
JPT Ref No: 62644164
Deadline: 15 Feb 2022
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.:
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Infliximab (genetical recombination) for intravenous infusion 100㎎ (100㎎×1vial/case) 807 cases,and 41 other contracts
Classification :
0004 Medical & Pharmaceutical Products 0032 Medical Supplies
Summay of Notice :
⑴ Official in charge of disbursement of the procuring entity : Takahiro Yoshida, Department of Finance, National Defense Medical College
⑵ Classification of the products to be procured : 4, 32
⑶ Nature and quantity of the products to be purchased :
①-1 Infliximab (genetical recombination) for intravenous infusion 100㎎ (100㎎×1vial/case) 807 cases
①-2 Pembrolizumab (genetical recombination) intravenous infusion 100㎎ (100㎎ 4mL×1vial/case) 212 cases
①-3 Vedolizumab (genetical recombination) for intravenous infusion 300㎎ (300㎎×1vial/case) 169 cases
①-4 Mepolizumab (genetical recombination) subcutaneous injection 100㎎ (100㎎×1pen/case) 217 cases
①-5 Ustekinumab (genetical recombination) subcutaneous injection 45㎎ (45㎎×1syringe/case) 101 cases
①-6 Denosumab (genetical recombination) subcutaneous injection 120㎎ (120㎎×1vial/case) 628 cases
①-7 Bevacizumab (genetical recombination) for intravenous infusion 400㎎/16mL (400㎎ 16mL×1vial/case) 208 cases
①-8 Tocilizumab (genetical recombination) for intravenous infusion 100㎎ (200㎎ 10mL×1vial/case) 656 cases
①-9 Letermovir tablets 240㎎ (240㎎×14tablets/case) 98 cases
①-10 Leuprorelin Acetate for injection kit 11.25㎎ (1...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Infliximab (Genetical Recombination) for Intravenous Infusion 100 (1001Vial/Case) 807 Cases,And 41 other Contracts - Japan Tender

The MINISTRY OF DEFENSE, a Government sector organization in Japan, has announced a new tender for Infliximab (Genetical Recombination) for Intravenous Infusion 100 (1001Vial/Case) 807 Cases,And 41 other Contracts. This tender is published on JapanTenders under JPT Ref No: 62644164 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2022-02-15.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.